Journal article
The cost implication of primary prevention in the HOPE 3 trial
Abstract
AIMS: The Heart Outcomes Prevention Evaluation-3 (HOPE-3) found that rosuvastatin alone or with candesartan and hydrochlorothiazide (HCT) (in a subgroup with hypertension) significantly lowered cardiovascular events compared with placebo in 12 705 individuals from 21 countries at intermediate risk and without cardiovascular disease. We assessed the costs implications of implementation in primary prevention in countries at different economic …
Authors
Lamy A; Lonn E; Tong W; Swaminathan B; Jung H; Gafni A; Bosch J; Yusuf S
Journal
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 5, No. 3, pp. 266–271
Publisher
Oxford University Press (OUP)
Publication Date
July 1, 2019
DOI
10.1093/ehjqcco/qcz001
ISSN
2058-5225